NOVELTY - A drug delivery ocular implant comprises: an elongate outer shell having a proximal end, a distal end, the outer shell is shaped to define an interior lumen; at least a first active drug positioned within the interior lumen, where the first active drug is present as at least one micro-tablet, where the micro-tablet have a density of 0.7-1.6 g/cc, where the micro-tablets have an aspect ratio of length to diameter of 2.8-3.6, where the outer shell comprises a first thickness; and where the outer shell comprises at least one region of drug release.    USE - For treating an ocular condition or disorder in an intraocular target tissue (claimed).    ADVANTAGE - The devices are capable of controlled release of drugs and also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the following:    (1) treating (M1) an ocular condition or disorder in an intraocular target tissue involves: making an opening in the temporal portion of an eye to access an anterior chamber of the eye; advancing a delivery device associated with the drug delivery ocular implant through the opening and across the anterior chamber of the eye, inserting the drug delivery ocular implant into eye tissue; positioning the implant such that at least one of the regions of drug release are located proximate an intraocular target; and withdrawing the delivery device from the eye, where drug elutes from the implant in sufficient quantity to treat an ocular condition or disorder;    (2) a composition for the treatment of an ocular disorder, comprising: a therapeutic agent having anti-vascular endothelial growth factor (VEGF) effects, where the anti-VEGF agent is formed into at least one micro-tablet, where the anti-VEGF agent is lyophilized prior to formation of the micro-tablets, where the anti-VEGF agent comprises at least 70 wt.% of the total weight of each micro-tablet; and where each micro-tablet has a density of 0.7-1.6 g/cc;    (3) a system for administering a therapeutic agent to an damaged or diseased eye, comprising: an ocular implant delivery apparatus comprising a proximal end, a distal end, and a cannula having an inner diameter of 23-25 gauge; an ocular implant comprising an elongate outer shell having a proximal end, a distal end, the outer shell being shaped to define an interior lumen, where the interior lumen is suitable for receiving micro-tablets, where the outer shell comprises a first thickness, where the outer shell comprises regions of drug release; and a therapeutic agent formed in at least one micro-tablet, the agent having anti-vascular endothelial growth factor (VEGF) effects, where the anti-VEGF agent is lyophilized prior to formation of the micro-tablets, where the anti-VEGF agent comprises at least 70 wt.% of the total weight of each micro-tablet; and where each micro-tablet has a density of 0.7-1.6 g/cc; and    (4) intravitreal injection (M2) of an agent for the treatment of an ocular disorder, involving: advancing to the surface of the sclera of an eye a delivery apparatus comprising a proximal end, a distal end, a cannula and containing micro-tablets comprising a therapeutic agent having anti-vascular endothelial growth factor (VEGF) effects, and an activator that functions to expel the contents of the cannula from the apparatus via passage through the proximal end; piercing the scleral surface to create a hole in the slcera; further advancing the delivery apparatus through the hole such that the proximal end is within the vitreal cavity of the eye; activating the activator to expel the anti-VEGF micro-tablets; and withdrawing the apparatus from the eye, thereby treating the disorder by the delivery of the anti-VEGF micro-tablets.